Related Experiment Video
Updated: Jun 20, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
[Gene therapy for heart failure].
José Luis Reyes-Juárez1, Angel Zarain-Herzberg
1Facultad de Medicina, Depto. de Bioquímica, Universidad Nacional Autónoma de México, México, D.F. México.
Archivos De Cardiologia De Mexico
|September 3, 2009
Summary
Gene therapy offers promising treatments for heart failure by correcting cellular defects. Research focuses on effective gene delivery methods like viral vectors for improved cardiac function.
Area of Science:
- Cardiovascular Research
- Molecular Medicine
- Biotechnology
Context:
- Heart failure (HF) research has significantly advanced in the last decade.
- Gene therapy is emerging as a leading strategy for HF treatment.
- Correcting cellular defects is key to successful HF therapy.
Purpose:
- To review the current literature on gene therapy for heart failure.
- To analyze future perspectives and challenges in the field.
- To discuss optimal gene delivery methods for myocardial applications.
Summary:
- Adenovirus and Adeno-associated virus vectors show high efficiency for myocardial gene delivery.
- Local administration routes are more effective than peripheral for cardiac gene therapy.
- Gene therapy targets mechanisms like calcium handling, apoptosis, and angiogenesis in HF.
Impact:
- Gene therapy holds potential for novel heart failure treatments.
- Optimizing gene delivery is crucial for therapeutic success.
- Understanding molecular pathways in HF enables targeted gene therapy approaches.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...